UA47505C2 - Спосіб лікування плоскоклітинного раку ротової порожнини за допомогою антагоністів лейкотриєну - Google Patents

Спосіб лікування плоскоклітинного раку ротової порожнини за допомогою антагоністів лейкотриєну Download PDF

Info

Publication number
UA47505C2
UA47505C2 UA99063226A UA99063226A UA47505C2 UA 47505 C2 UA47505 C2 UA 47505C2 UA 99063226 A UA99063226 A UA 99063226A UA 99063226 A UA99063226 A UA 99063226A UA 47505 C2 UA47505 C2 UA 47505C2
Authority
UA
Ukraine
Prior art keywords
alkyl
ethyl
solvate
phenyl
acceptable salt
Prior art date
Application number
UA99063226A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Джером Герберт Флайш
Уільям Томас Джексон
Джейсон Скотт Сойєр
Джейсон Скотт Сойер
Original Assignee
Елі Ліллі Енд Компані
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Елі Ліллі Енд Компані, Эли Лилли Энд Компани filed Critical Елі Ліллі Енд Компані
Publication of UA47505C2 publication Critical patent/UA47505C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
UA99063226A 1996-12-13 1997-02-12 Спосіб лікування плоскоклітинного раку ротової порожнини за допомогою антагоністів лейкотриєну UA47505C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3426996P 1996-12-13 1996-12-13
US4087497P 1997-03-21 1997-03-21
PCT/US1997/021953 WO1998025615A1 (en) 1996-12-13 1997-12-02 Leukotriene antagonists for oral squamous cell carcinoma

Publications (1)

Publication Number Publication Date
UA47505C2 true UA47505C2 (uk) 2002-07-15

Family

ID=26710754

Family Applications (1)

Application Number Title Priority Date Filing Date
UA99063226A UA47505C2 (uk) 1996-12-13 1997-02-12 Спосіб лікування плоскоклітинного раку ротової порожнини за допомогою антагоністів лейкотриєну

Country Status (14)

Country Link
EP (1) EP0964683A4 (de)
JP (1) JP2001509142A (de)
KR (1) KR20000069452A (de)
CN (1) CN1245429A (de)
AU (1) AU726215B2 (de)
CA (1) CA2274855A1 (de)
EA (1) EA002742B1 (de)
IL (1) IL130304A0 (de)
NO (1) NO992846L (de)
NZ (1) NZ335922A (de)
PL (1) PL334241A1 (de)
TR (1) TR199901307T2 (de)
UA (1) UA47505C2 (de)
WO (1) WO1998025615A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009700A1 (en) 2000-07-28 2002-02-07 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
US8093253B2 (en) * 2008-03-06 2012-01-10 Hoffmann-La Roche Inc. Leukotriene B4 inhibitors
KR101898879B1 (ko) 2014-03-05 2018-09-14 재단법인 진안홍삼연구소 홍삼 가공 추출물을 유효성분으로 함유하는 구강편평세포암의 예방, 개선 또는 치료를 위한 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6372648A (ja) * 1986-09-16 1988-04-02 Sumitomo Pharmaceut Co Ltd 新規不飽和脂肪酸誘導体
PH30449A (en) * 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists
CZ276694A3 (en) * 1991-11-25 1995-11-15 Lilly Co Eli Process for preparing diphenyl derivative

Also Published As

Publication number Publication date
IL130304A0 (en) 2000-06-01
TR199901307T2 (xx) 1999-08-23
NO992846D0 (no) 1999-06-11
KR20000069452A (ko) 2000-11-25
CN1245429A (zh) 2000-02-23
JP2001509142A (ja) 2001-07-10
NZ335922A (en) 2000-12-22
EA002742B1 (ru) 2002-08-29
WO1998025615A1 (en) 1998-06-18
AU7845198A (en) 1998-07-03
AU726215B2 (en) 2000-11-02
EA199900543A1 (ru) 2000-02-28
EP0964683A1 (de) 1999-12-22
EP0964683A4 (de) 2002-08-14
PL334241A1 (en) 2000-02-14
NO992846L (no) 1999-06-11
CA2274855A1 (en) 1998-06-18

Similar Documents

Publication Publication Date Title
CA2207333C (en) Use of nebivolol as an anti-atherogenic
JP6240075B2 (ja) 骨粗しょう症の治療方法
US5910505A (en) Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma
KR0161300B1 (ko) 뼈 손실 예방에 유용한 벤조티오펜
KR101819567B1 (ko) 혈관신생-매개된 질환의 치료용 화합물
JP2011518174A (ja) エストロゲン受容体に関連する疾患を処置するための化合物及び方法
JPH11511127A (ja) 抗腫瘍剤としてのフェノール置換ジホスホネートの使用
EP3458448B1 (de) Fasn-hemmer zur behandlung der nicht-alkoholischen steatohepatitis
JP2017535608A (ja) 癌標的化薬物ビヒクルとしてのリン脂質エーテル類似体
WO2013130625A1 (en) Phospho-ester derivatives and uses thereof
JPH07215871A (ja) 血清コレステロールを減少させるための方法
JP2005516938A (ja) イソインジゴ、インジゴおよびインジルビンの誘導体、ならびに癌治療における使用
UA47505C2 (uk) Спосіб лікування плоскоклітинного раку ротової порожнини за допомогою антагоністів лейкотриєну
CA2944517C (en) Method for treating chronic lymphocytic leukemia
US20240139149A1 (en) Therapeutic uses of urolithin derivatives
TWI717712B (zh) 新穎化合物及包含其之用於預防或治療肥胖或代謝症候群的藥學組成物
JPH09169664A (ja) 分化誘導作用を有する薬剤
TWI306760B (en) Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
CA2794581C (en) Method of treating osteoporosis
EP1784173A1 (de) Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat-derivaten
KR20050044582A (ko) 위식도 역류 질환의 치료를 위한 신규한 용도
CN116589502B (zh) 一种四价铂类免疫原性死亡诱导剂及其制备方法与应用
JP5313971B2 (ja) 5−置換4,7−ジメトキシ−1,3−ベンゾジオキソール(5−Substituted4,7−dimethoxy−1,3−benzodioxoles)の結腸直腸癌(colorectalcancer)治療用医薬品
CN106995368B (zh) 一种非atp竞争性fgfr1抑制剂及其应用
JPWO2019031425A1 (ja) 運動ニューロン疾患治療剤